This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FSDC vs. GMTX, MOR, ZYME, CALT, SBTX, ETHZ, AVTE, NLTX, BIOA, and VIRIShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Gemini Therapeutics (GMTX), MorphoSys (MOR), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Silverback Therapeutics (SBTX), Flag Ship Acquisition (ETHZ), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), and Virios Therapeutics (VIRI). FS Development vs. Its Competitors Gemini Therapeutics MorphoSys Zymeworks Calliditas Therapeutics AB (publ) Silverback Therapeutics Flag Ship Acquisition Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Virios Therapeutics Gemini Therapeutics (NASDAQ:GMTX) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Is GMTX or FSDC more profitable? FS Development's return on equity of 0.00% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% FS Development N/A N/A N/A Does the media favor GMTX or FSDC? In the previous week, Gemini Therapeutics had 1 more articles in the media than FS Development. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for FS Development. Gemini Therapeutics' average media sentiment score of 0.67 beat FS Development's score of 0.00 indicating that Gemini Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Gemini Therapeutics Positive FS Development Neutral Which has stronger valuation and earnings, GMTX or FSDC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-69.90FS DevelopmentN/AN/AN/AN/AN/A Do institutionals and insiders hold more shares of GMTX or FSDC? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of FS Development shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryGemini Therapeutics and FS Development tied by winning 3 of the 6 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$900.65M$787.62M$6.05B$10.30BDividend YieldN/A4.84%5.73%4.82%P/E RatioN/A1.2885.3127.10Price / SalesN/A29.85601.46133.24Price / CashN/A17.6425.7730.18Price / BookN/A7.5412.676.69Net IncomeN/A-$7.59M$3.32B$276.55M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$71.96+2.9%N/A+46.4%$900.65MN/A0.00N/AGMTXGemini TherapeuticsN/A$70.28+3.5%N/A+46.4%$3.05BN/A-70.2830High Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ZYMEZymeworks0.0662 of 5 stars$16.70+0.1%N/AN/A$1.26B$76.30M-17.22460Analyst UpgradeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180SBTXSilverback TherapeuticsN/A$10.33+0.6%N/A-22.0%$372.48MN/A-4.2783High Trading VolumeETHZFlag Ship AcquisitionN/A$2.20-5.2%N/AN/A$361.75MN/A-0.157Gap UpAVTEAerovate TherapeuticsN/A$9.04-1.1%N/A-87.8%$262.02MN/A-3.0220High Trading VolumeNLTXNeoleukin TherapeuticsN/A$23.47+1.6%N/A-38.9%$220.57MN/A-7.5590High Trading VolumeBIOABioAge Labs0.182 of 5 stars$5.52-2.6%N/AN/A$197.93MN/A0.00N/AVIRIVirios TherapeuticsN/A$6.38-5.6%N/A+30.3%$122.87MN/A-23.635Gap Down Related Companies and Tools Related Companies Gemini Therapeutics Competitors MorphoSys Competitors Zymeworks Competitors Calliditas Therapeutics AB (publ) Competitors Silverback Therapeutics Competitors Flag Ship Acquisition Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors BioAge Labs Competitors Virios Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneInvestors are quietly piling into this secret AI stock Elon hates… It's one of those things you just need t...Economic Media | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
